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antimicrobial treatment for infection with multidrug-resis-
tant Shigella spp. Patients should avoid sex during symp-
tomatic infections and wait for 2 negative stool cultures. 
Montreal public health officials investigated and counselled 
this patient as they do for every patient with Shigella infec-
tions. In Quebec, physicians and microbiology laboratories 
are notified of Shigella clusters and multidrug-resistant Shi-
gella infections.
To our knowledge, no other ciprofloxacin-resistant and 
azithromycin-nonsusceptible Shigella flexneri isolates have 
been documented in the province of Quebec. No PFGE 
matches to S. flexneri serotype 2a pulsovar 21 have been 
identified in Canada. Multidrug-resistant Shigella isolates, 
including those with both resistance to ciprofloxacin and 
nonsusceptibility to azithromycin, may be underestimated 
and incidence may be increasing (1,3–5).
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To the Editor: Throughout the world, ≈115 million 
persons have hepatitis C virus (HCV) antibodies, ≈37 mil-
lion are infected with HIV type 1, and an estimated 2.3 
million persons are infected with both viruses (1). The 
estimated prevalence of HIV infection among adults in 
Malawi is 9.1% (2). Data concerning HCV seroprevalence 
in Malawi are conflicting and range from 0.0% to 18.0%, 
depending on the studied population and the chosen meth-
ods for HCV infection diagnosis (3–6). In a recent study, 
researchers used stored blood samples (without HCV con-
firmatory assays) from studies in rural and urban Malawian 
populations (1989–2008); an HCV seroprevalence of 6.8% 
was found in HIV-positive patients (7). In contrast, in a 
cohort of HIV-negative mothers (2006–2010), only 0.5% 
were found to be HCV positive with confirmatory HCV 
testing by immunoblot (8). These studies were not included 
in a 2015 metaanalysis that estimated the seroprevalence of 
HCV infection and HIV/HCV co-infection in Malawi to be 
7.7% and 2.0%, respectively (9). Liver disease progress-
es more rapidly in HIV/HCV co-infected patients than in 
HCV monoinfected patients (10), and the highly effective 
second-generation direct-acting antiviral therapies are less 
toxic than interferon-based treatment regimens. It is crucial 
to gather accurate epidemiologic information on the burden 
of HIV/HCV co-infection to support the design and imple-
mentation of HCV treatment initiatives in resource-limited 
settings such as sub-Saharan Africa.
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The aim of our study was to evaluate the prevalence 
of HIV/HCV co-infection in HIV-positive adults. We used 
baseline data obtained during the first 4 months of the 
ongoing observational, prospective Lighthouse Tenofo-
vir Cohort (LighTen) study (Clinicaltrials.gov identifier: 
NCT02381275), which is conducted at the Lighthouse 
Clinic in Lilongwe, Malawi, in cooperation with the Insti-
tute of Public Health, University of Heidelberg, Germany, 
together with the Division of Infectious Diseases and the 
Clinic for Gastroenterology and Hepatology, University 
Hospital of Cologne, Germany. Ethical approvals by the 
respective committees of the Research Commission of the 
Ministry of Health, Malawi, and the participating German 
universities were granted before the study was initiated. A 
patient was included if he or she had confirmed HIV infec-
tion, was >18 years of age, and had given written informed 
consent for study participation. We included patient demo-
graphic information, medical history, concomitant diseas-
es, bodyweight and height, as well hepatic panel results, 
platelet count, estimated glomerular filtration rate (deter-
mined by the CKD Epi formula), hemoglobin level, leu-
kocyte count, CD4 cell count, and quantitative HIV RNA 
(Roche COBAS TaqMan HIV-1 v2.0, Risch, Switzerland) 
recorded at patient enrollment from the Kamuzu Central 
Hospital, Lilongwe, Malawi.
Aliquots of blood samples were stored at -80°C and 
kept on dry ice during airfreight to Cologne, then stored 
at -80°C until testing. Samples were thawed and tested for 
HCV IgG by a chemiluminescent micro-particle immuno-
assay (Abbott ARCHITECT, Wiesbaden, Germany) at the 
Institute of Virology, University of Cologne, Germany. 
Specimens that reacted to this immunoassay underwent 
supplemental testing with PCR for HCV RNA by a quan-
titative assay (Abbott RealTime HCV). We analyzed base-
line characteristics of the study population (Table) using 
descriptive statistics (SPSS software version 22; IBM Inc., 
Chicago, IL, USA).
All 227 patients (137 female, median age 36.1 years) 
were HIV positive, with a median quantitative HIV RNA of 
44,389 copies/mL and median CD4 cell counts of 284 cells/
µL. Twenty-two patients (9.7%) had a history of blood 
transfusion, and 0.9% had a history of jaundice. Results 
for alanine aminotransferase level, aspartate aminotrans-
ferase level, total bilirubin level, and platelet counts were 
within the reference range in almost all patients, and no 
patient was jaundiced. Five patients (2.2%) had HCV IgG. 
However, none of these patients had detectable HCV RNA. 
Thus, the prevalence of active HIV/HCV co-infection was 
0% in the studied cohort. One of the 5 patients who were 
positive for IgG against HCV also had a history of blood 
transfusion; none had a history of jaundice, and all but 1 
seropositive patient had liver function tests within the ref-
erence range.
Three studies in Malawi have used PCR to test for 
HCV: 2 studies in HIV-positive pregnant women (includ-
ed in the aforementioned metaanalysis) (9) and 1 study in 
blood donors (5), of whom 10.7% were HIV infected. PCR 
results for HCV RNA were positive in 0/2,041 (0%), 1/309 
(0.3%), and 1/140 (0.7%) of these cases. Our findings con-
firm this low prevalence of PCR-positive active HCV in-
fection also among HIV-infected adults from the general 
population of urban Lilongwe. Together, these studies indi-
cate an overestimation of HCV prevalence on the basis of 
screening assays (7). 
From a public health point of view, HCV infection as 
a cause of liver-related illness seems of minor importance 
in Malawi. The fact that HCV prevalence in antenatal care 
cohorts with already established serum sampling for rou-
tine HIV testing is similar to that in this mixed cohort of 
urban Malawi residents suggests that samples from these 
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Table. Characteristics of HIV-positive adults with HIV/HCV co-infection, Malawi* 
Characteristic 
HIV-positive and HCV antibody–
negative patients, n = 222 
HIV-positive and HCV-antibody–
positive patients, n = 5 
Age, y 36.1 (30.5–41.5) 34.5 (24.8–50.2) 
Sex, M/F 88/134 (40/60) 2/3 (40/60) 
Weight, kg, n = 167 59.1 (52.7–66.7) 59.6 (55.9–68.7) 
Height, cm, n = 170 157.0 (151.0–165.0) 159.5 (151.0–167.0) 
Quantitative HIV RNA [<40]  103, copies/mL, n = 205 44.43 (12.09–158.96) 30.87 (21.14–95.38) 
History of blood transfusion 21 (9) 1(20) 
History of jaundice 2 (1) 0  
eGFR mL/min/1,73 qm, n = 194 96.0 (79.0–110.0) 91.0 (88.0–94.0) 
ALT [7–35], IU/L, n = 183 23.3 (14.9–33.4) 15.6 (13.2–22.5) 
AST [≤38], IU/L, n = 183 31.7 (23.0–42.4) 31.9 (23.2–43.7) 
Total bilirubin level [≤1.3], mg/dL, n = 185 0.30 (0.20–0.45) 0.26 (0.20–0.48) 
Platelet count [122–330] × 109/L, n = 214 226 (181–293) 283 (160–320) 
Hemoglobin level [10.9–17.3], g/dL, n = 215 12.4 (10.8–13.7) 13.3 (11.8–15.1) 
Leukocyte count [2,800–8,400], cells/µL, n = 213 4,400 (3,500–5,400) 3,900 (2,700–6,600) 
CD4 cell count, cells/µL, n = 139 284 (101–421) 319 (189–449) 
*Values are given as total no. (%) or as median with interquartile range for the HCV antibody–negative study population and median with range for the 
HCV antibody–positive study population, respectively. Reference values are given in brackets. Number of missing values for the HCV-antibody negative 
patients ranged from 88 to 3, indicated by differing patient numbers in stub column. ALT, alaninine aminotransferase; AST, aspartate aminotransferase; 
eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus. 
 
programs might represent a cost-efficient opportunity for 
monitoring trends of HCV infection in the population.
The study was funded by the Hector Stiftung, Mannheim,  
Germany, Project M72 and the Cologne/Heidelberg/Lighthouse 
Partnership through ESTHER, Germany, Deutsche Gesellschaft 
für Internationale Zusammenarbeit (GIZ), contract no.: 81 166 383.
References
  1. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K,  
McGowan C, et al. Prevalence and burden of HCV co-infection  
in people living with HIV: a global systematic review  
and meta-analysis. Lancet Infect Dis. 2016;16:797–808.  
http://dx.doi.org/10.1016/S1473-3099(15)00485-5
  2. Joint United Nations Programme on HIV/AIDS. Malawi: HIV and 
AIDS estimates (2015). [cited 2016 Jul 7]. http://www.unaids.org/
en/regionscountries/countries/malawi 
  3. Ahmed SD, Cuevas LE, Brabin BJ, Kazembe P, Broadhead R, 
Verfoeff FH, et al. Seroprevalence of hepatitis B and C in HIV 
and HIV in Malawian pregnant women. J Infect. 1998;37:248–51. 
http://dx.doi.org/10.1016/S0163-4453(98)91983-1
  4. Maida MJ, Costello Daly C, Hoffman I, Cohen MS, Kumwenda M, 
Vernazza PL. Prevalence of hepatitis C infection in Malawi and lack 
of association with sexually transmitted diseases. Eur J Epidemiol. 
2000;16:1183–4. http://dx.doi.org/10.1023/A:1010920426795
  5. Candotti D, Mundy C, Kadewele G, Nkhoma W, Bates I, Allain JP. 
Serological and molecular screening for viruses in blood donors 
from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of 
markers of hepatitis B and C viruses. J Med Virol. 2001;65:1–5. 
http://dx.doi.org/10.1002/jmv.1093
  6. Chimphambano C, Komolafe IOO, Muula AS. Prevalence of HIV, 
HepBsAg and Hep C antibodies among inmates in Chichiri prison, 
Blantyre, Malawi. Malawi Med J. 2007;19:107–10.
  7. Taha TE, Rusie LK, Labrique A, Nyirenda M, Soko D, Kamanga M,  
et al. Seroprevalence for hepatitis E and other viral hepatitides  
among diverse populations, Malawi. Emerg Infect Dis. 
2015;21:1174–82. http://dx.doi.org/10.3201/eid2107.141748
  8. Fox JM, Newton R, Bedaj M, Ada Keding, Molyneux E,  
Carpenter LM, et al. Prevalence of hepatitis C virus in mothers and 
their children in Malawi. Trop Med Int Health. 2015;20:638–42. 
http://dx.doi.org/10.1111/tmi.12465
  9. Rao VB, Johari N, du Cros P, Messina J, Ford N, Cooke GS. 
Hepatitis C seroprevalence and HIV co-infection in  
sub-Saharan Africa: a systematic review and meta-analysis.  
Lancet Infect Dis. 2015;15:819–24. http://dx.doi.org/10.1016/
S1473-3099(15)00006-7
10. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. 
Influence of human immunodeficiency virus infection on the course 
of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 
2001;33:562–9. http://dx.doi.org/10.1086/321909
Address for correspondence: Münevver Demir, Clinic for Gastroenterology 
and Hepatology, University Hospital of Cologne, Germany, D-50924, 
Koeln, Germany; email: muenevver.demir@uk-koeln.de
Exposures among MERS 
Case-Patients, Saudi Arabia, 
January–February 2016
Raafat F. Alhakeem, Claire M. Midgley,  
Abdullah M. Assiri, Mohammed Alessa,  
Hassan Al Hawaj, Abdulaziz Bin Saeed,  
Malak M. Almasri, Xiaoyan Lu, Glen R. Abedi, 
Osman Abdalla, Mutaz Mohammed,  
Homoud S. Algarni, Hail M. Al-Abdely,  
Ali Abraheem Alsharef, Randa Nooh,  
Dean D. Erdman, Susan I. Gerber, John T. Watson
Author affiliations: Ministry of Health, Riyadh, Saudi Arabia  
(R.F. Alhakeem, A.M. Assiri, M. Alessa, H. Al Hawaj, A. Bin Saeed, 
M.M. Almasri, O. Abdalla, M. Mohammed, H.S. Algarni,  
H.M. Al-Abdely, A.A. Alsharef, R. Nooh); US Centers for Disease 
Control and Prevention, Atlanta, Georgia, USA (C.M. Midgley,  
X. Lu, G.R. Abedi, D.D. Erdman. S.I. Gerber, J.T. Watson)
DOI: http://dx.doi.org/10.3201/eid2211.161042
To the Editor: Risk factors for primary acquisition 
of Middle East respiratory syndrome (MERS) coronavirus 
(CoV) include recent direct contact with dromedary camels 
(1), but secondary transmission, associated with healthcare 
settings (2–4) or household contact (5), accounts for most 
reported cases. Because persons with MERS often do not 
report any of these risk factors, we investigated MERS 
cases in Saudi Arabia during an apparent period of limited 
hospital transmission. Through telephone interviews of 
case-patients and information from routine investigations, 
we aimed to characterize exposures and to explore addi-
tional factors potentially important in disease transmission. 
We also genetically sequenced MERS-CoV from respira-
tory specimens to identify circulating strains.
For confirmed MERS cases (6) reported in Saudi Ara-
bia during January–February 2016, we assessed exposures 
during the 2 weeks before illness onset (exposure period), 
including direct (1) and indirect camel contact; indirect con-
tact was defined as 1) having visited settings where camels 
were kept but without having direct contact or 2) exposure 
to friends or household members who themselves had di-
rect camel exposure (1). We assessed whether case-patients 
had worked at, visited, or been admitted to a healthcare set-
ting or had contact with a person known to have MERS 
during the case-patient’s exposure period. We also asked 
about recent travel and if any household members were 
healthcare personnel. For persons too ill to participate or 
deceased, we interviewed relatives or close friends.
We classified as secondary any case identified through 
routine case-contact tracing and testing. We considered 
persons whose cases were identified through routine testing 
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